A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0
|
作者：
Yuan, Li
Shu, Pei
Li, Xiaoyu
Li, Guiling
Zhang, Keqiang
Lai, Lin
Hong, Jinsheng
Huang, Chu-Ying
Wang, Yongsheng
Xie, Hui
Zheng, Li
Zhou, Qi
机构：
[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Hunan Canc Hosp, Changsha, Peoples R China
[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China
[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5509
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Palomid 529, a Combined TORC1/TORC2 Inhibitor, Suppresses Spasms in a Rat Model of Infantile Spasms
    Galanopoulou, Aristea S.
    Sherris, David
    ANNALS OF NEUROLOGY, 2010, 68 (04) : S39 - S39
  • [22] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
    LoRusso, P.
    Markman, B.
    Tabernero, J.
    Shazer, R.
    Nguyen, L.
    Heath, E.
    Patnaik, A.
    Papadopoulos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    Hong, David S.
    Choe, Jennifer Hsing
    Naing, Aung
    Wheler, Jennifer J.
    Falchook, Gerald S.
    Piha-Paul, Sarina
    Moulder, Stacy L.
    George, Goldy C.
    Choe, Jonathan M.
    Strauss, Lewis C.
    Gallick, Gary E.
    Kurzrock, Razelle
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 918 - 926
  • [24] A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    David S. Hong
    Jennifer Hsing Choe
    Aung Naing
    Jennifer J. Wheler
    Gerald S. Falchook
    Sarina Piha-Paul
    Stacy L. Moulder
    Goldy C. George
    Jonathan M. Choe
    Lewis C. Strauss
    Gary E. Gallick
    Razelle Kurzrock
    Investigational New Drugs, 2013, 31 : 918 - 926
  • [25] Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
    Kang, Yoon-Koo
    Ryu, Min -Hee
    Hong, Yong Sang
    Choi, Chang-Min
    Kim, Tae Won
    Ryoo, Baek-Yeol
    Kim, Jeong Eun
    Weis, John R.
    Kingsford, Rachel
    Park, Cheol Hee
    Jang, Seong
    Mcginn, Arlo
    Werner, Theresa L.
    Sharma, Sunil
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 743 - 750
  • [26] Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
    Patel, Sandip P.
    Alonso-Gordoa, Teresa
    Banerjee, Susana
    Wang, Ding
    Naidoo, Jarushka
    Standifer, Nathan E.
    Palmer, Doug C.
    Cheng, Lin-Yang
    Kourtesis, Panagiotis
    Ascierto, Maria L.
    Das, Mayukh
    Diamond, Jennifer R.
    Hellmann, Matthew D.
    Carneiro, Benedito A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [27] Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228
    Paik, Paul K.
    Fan, Pang-Dian
    Qeriqi, Besnik
    Namakydoust, Azadeh
    Daly, Bobby
    Ahn, Linda
    Kim, Rachel
    Plodkowski, Andrew
    Ni, Ai
    Chang, Jason
    Fanaroff, Rachel
    Ladanyi, Marc
    de Stanchina, Elisa
    Rudin, Charles M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 516 - 526
  • [28] Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
    Paik, Paul K.
    Ahn, Linda Su Hyun
    Ginsberg, Michelle S.
    Plodkowski, Andrew J.
    Kim, Rachel
    Doyle, L. Austin
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] A Phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: Preliminary results for patients with advanced cervical cancer (POD1UM-101)
    Mehnert, Janice
    Paz Ares, Luis
    Pikiel, Joanna
    Banerji, Udai
    Kryzhanivska, Anna
    Lakhani, Nehal
    Ochsenreiter, Sebastian
    Arkenau, Tobias
    Bourayou, Nawel
    Kornacki, Deanna
    Tian, Chuan
    Condamine, Thomas
    Gardeazabal Gonzalez, Itziar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Phase I/II study of CTLA-4 inhibitor AGEN1884 1 PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
    Coward, J.
    Lemech, C.
    Meniawy, T.
    Dupont, C. D.
    Gonzalez, A. M.
    Lim, M.
    Savitsky, D.
    Carini, M.
    Hu, S.
    Shebanova, O.
    Dow, E.
    Ortuzar, W.
    Buell, J. S.
    Stein, R. B.
    Youssoufian, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 417 - 417
12345